ARCHIVES

Bristol Stock Drops Amid New Setbacks, Deepening Firm’s Decline In Oncology

This article is from The Cancer Letter archive.

Vol. 28 No. 14 | April 5, 2002

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities (8-page issue).

April 18, 2003

Senate Vote On Override Of NIH Reauthorization Veto Delayed Until After US-USSR Summit Meeting

November 22, 1985

IOM Panel Suggest Ways To Fund More Training, Construction

November 9, 1990

Adding Avastin Did Not Improve Standard Chemotherapy Regimen

April 27, 2012

Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease

January 27, 2012

FDA to elevate oncology to office level, consolidate most cancer programs. Search planned for oncologist to head new office.

July 23, 2004